← Back to Screener
Lisata Therapeutics, Inc. Common Stock (LSTA)
Price$3.37
Favorite Metrics
Price vs S&P 500 (26W)54.51%
Price vs S&P 500 (4W)-25.78%
Market Capitalization$30.44M
All Metrics
Book Value / Share (Quarterly)$1.68
P/TBV (Annual)1.10x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-78.84%
Cash Flow / Share (Quarterly)$-1.81
Price vs S&P 500 (YTD)112.95%
Gross Margin (TTM)9.52%
Net Profit Margin (TTM)-4478.24%
EPS (TTM)$-1.91
10-Day Avg Trading Volume0.10M
EPS Excl Extra (TTM)$-1.91
Revenue Growth (5Y)-58.81%
EPS (Annual)$-1.91
ROI (Annual)-111.65%
Gross Margin (Annual)9.56%
Net Profit Margin (5Y Avg)-2537.24%
Cash / Share (Quarterly)$1.81
Revenue Growth QoQ (YoY)-90.00%
ROA (Last FY)-93.47%
Revenue Growth TTM (YoY)-27.06%
EBITD / Share (TTM)$-2.10
ROE (5Y Avg)-66.74%
Operating Margin (TTM)-4674.71%
Cash Flow / Share (Annual)$-1.81
P/B Ratio2.05x
P/B Ratio (Quarterly)1.10x
Net Income / Employee (Annual)$-1
Net Interest Coverage (TTM)-1616.00x
ROA (TTM)-70.85%
EPS Incl Extra (Annual)$-1.91
Current Ratio (Annual)5.76x
Quick Ratio (Quarterly)5.20x
3-Month Avg Trading Volume0.14M
52-Week Price Return104.59%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.68
P/S Ratio (Annual)179.05x
Asset Turnover (Annual)0.01x
52-Week High$5.07
Operating Margin (5Y Avg)-2806.21%
EPS Excl Extra (Annual)$-1.91
CapEx CAGR (5Y)6.96%
Tangible BV CAGR (5Y)5.57%
26-Week Price Return58.50%
Quick Ratio (Annual)5.20x
13-Week Price Return92.79%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)5.76x
Enterprise Value$14.483
Revenue / Share Growth (5Y)-83.48%
Asset Turnover (TTM)0.01x
Book Value / Share Growth (5Y)-36.18%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)0.82x
Pretax Margin (Annual)-10322.35%
Cash / Share (Annual)$1.81
3-Month Return Std Dev181.11%
Gross Margin (5Y Avg)11.85%
Net Income / Employee (TTM)$-1
ROE (Last FY)-111.65%
Net Interest Coverage (Annual)-71.89x
EPS Basic Excl Extra (Annual)$-1.91
P/FCF (TTM)6.78x
Receivables Turnover (TTM)0.38x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.91
Receivables Turnover (Annual)0.38x
ROI (TTM)-84.39%
P/S Ratio (TTM)179.05x
Pretax Margin (5Y Avg)-2682.23%
Revenue / Share (Annual)$0.02
Tangible BV / Share (Annual)$1.68
Price vs S&P 500 (52W)74.76%
Year-to-Date Return115.59%
5-Day Price Return-19.80%
EPS Normalized (Annual)$-1.91
ROA (5Y Avg)-58.26%
Net Profit Margin (Annual)-9756.47%
Month-to-Date Return-19.96%
Cash Flow / Share (TTM)$-2.66
EBITD / Share (Annual)$-2.10
Operating Margin (Annual)-10711.18%
LT Debt / Equity (Annual)0.55x
ROI (5Y Avg)-66.74%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.91
P/TBV (Quarterly)1.10x
P/B Ratio (Annual)1.10x
Inventory Turnover (TTM)1.23x
Pretax Margin (TTM)-4478.24%
Book Value / Share (Annual)$1.68
Price vs S&P 500 (13W)92.10%
Beta1.03x
P/FCF (Annual)30.14x
Revenue / Share (TTM)$0.02
ROE (TTM)-84.39%
52-Week Low$1.81
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.11
4.11
4.11
4.11
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
LSTALisata Therapeutics, Inc. Common Stock | 179.05x | -27.06% | 9.52% | — | $3.37 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Lisata Therapeutics is a clinical-stage biopharmaceutical company developing novel therapies for solid tumors. Its lead candidate, certepetide, is designed to activate a proprietary uptake pathway that enhances the ability of co-administered anti-cancer drugs to penetrate and target solid tumors more effectively.